Rocket Lab's Classified 'Curveball' Launch Meets a Brutal Market Reality: Insider Sales, Macro Headwinds, and a SpaceX IPO Shadow

Rocket Lab shares slide over 10% as SpaceX IPO, hot jobs report, and insider sales overshadow its hypersonic test mission and $2.2B backlog.

Rocket Lab is hours away from firing off its next hypersonic test mission, but the stock is already taking hits from all sides. The company's shares tumbled sharply on Tuesday, sliding more than 10% to €87.90 in a session that saw the equity give up early gains and test levels not seen since before the May rally. The selloff came as multiple catalysts — a looming SpaceX IPO, a hotter-than-expected jobs report, and a concentrated wave of insider selling — converged to batter the space-sector proxy.

The upcoming "Curveball" mission, scheduled for Wednesday evening local time from Wallops Flight Facility in Virginia, is anything but routine. It is a suborbital flight under the HASTE program (Hypersonic Accelerator Suborbital Test Electron), using a modified Electron rocket to carry a classified payload for government and intelligence clients. The launch is part of a broader $190 million contract Rocket Lab secured with the US Department of Defense earlier this year for 20 such flights over four years. This is not a one-off — it is a running partnership that underscores the company's deepening ties with the defense establishment. Separately, Rocket Lab confirmed a $90 million contract with the US Space Force on June 7, pushing its total order backlog to $2.2 billion, up 108% year-on-year.

Yet for all that momentum on the operational front, the stock is being dragged down by forces outside Rocket Lab's control. The most immediate is the long-anticipated SpaceX IPO, set to begin trading on Friday, June 12. What was supposed to be a rising tide for the entire space sector has turned into a source of anxiety. SpaceX trimmed its target valuation from roughly $2 trillion to $1.77 trillion, and that adjustment, combined with a Blue Origin rocket explosion that dented industry confidence, has triggered a rotation out of space names. Some market participants worry about a "sell the news" effect once SpaceX shares become directly tradable.

Adding to the macro pressure, the Bureau of Labor Statistics reported on Friday that the US economy added 172,000 non-farm jobs in May — more than double the 80,000 that economists had penciled in. A robust labor market raises the odds that the Federal Reserve will keep interest rates elevated, a headwind for growth stocks like Rocket Lab that depend on future earnings expansion for their valuations.

At the same time, a flurry of insider stock sales has spooked retail and institutional holders alike. Between May 28 and June 1, several top executives — including the general counsel and the chief operating officer — cashed in shares worth a combined $18 million. Director Alexander Slusky alone sold 60,000 shares for roughly $9 million. Marvin Clevenger, president of Rocket Lab USA, unloaded 3,500 shares for approximately $513,000. All transactions were executed under pre-arranged 10b5-1 trading plans, so they carry no legal stigma, but the concentration of sales so close to the stock's 52-week high has rattled investors. Over the past 90 days, insider net selling has reached nearly $35 million.

The picture is not uniformly dark. Rocket Lab's first-quarter 2026 results, reported in May, showed revenue surging 63.5% to $200.3 million and gross margin expanding to 38.2%. The company holds more than $1 billion in net liquidity. Analysts remain broadly bullish: 86% of the 15 covering the stock rate it a buy, with not a single sell recommendation. Stifel's Erik Rasmussen reiterated his buy call on Tuesday and lifted his price target to $132, the highest on the street, citing the growing portfolio of launch services and complex spacecraft systems. On the institutional side, the Winton Group built a new position of roughly 25,900 shares, signaling that some deep-pocketed investors see value in the pullback.

Technically, the stock has fallen more than 34% from its all-time high of €133.80 reached in late May. Earlier in the day, it had been trading around €93.10, roughly 10% above its 50-day moving average of €85, but the late-session rout pushed it below that key support level; the 50-day average currently sits at €84.89, only a hair below the closing price. The relative strength index at 44.8 points to neutral territory, suggesting the selling is not yet oversold.

Wednesday's Curveball launch will act as a short-term sentiment gauge. A smooth, successful flight would reinforce Rocket Lab's credibility in the hypersonic defense niche and could help stem the bleeding. A failure would add another layer of pressure. But the bigger test lies ahead: whether Rocket Lab can navigate the distraction of a SpaceX IPO rotation, absorb the macro rate headwinds, and convince the market that its independent story — anchored by defense contracts, a $2.2 billion backlog, and the upcoming Neutron rocket debut in late 2026 — still merits a premium valuation.